COMMUNIQUÉS West-GlobeNewswire

Digbi Health Publishes Peer-Reviewed Data Demonstrating Significant Cost Savings for Employers Via Its Precision Biology Telehealth Platform to Manage GLP-1, Metabolic, and GI Costs
15/01/2026
Actuarial claims analysis confirms up to 9X ROI across GLP-1, Metabolic, and GI Costs, demonstrating the power of gut microbiome and genetics-based biomarker care MOUNTAIN VIEW, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE [...]
Stablepharma and AFT Pharmaceuticals (NZX: AFT; ASX: AFP) partner to address multi-billion dollar anti-infective and oncology therapeutics market
15/01/2026
LONDON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Stablepharma Limited, specialists in thermostable formulations, today announced a development and option-to-license agreement with AFT Pharmaceuticals to develop a portfolio of [...]
Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy
15/01/2026
Commercial launch in Switzerland anticipated in H2 2026 Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved [...]
Communiqué de presse : Myqorzo et Redemplo approuvés en Chine
15/01/2026
Myqorzo et Redemplo approuvés en Chine Approbation de Myqorzo pour la cardiomyopathie hypertrophique obstructive et de Redemplo pour le syndrome de chylomicronémie familiale. Souligne l’engagement à long terme de Sanofi [...]
Press Release: Myqorzo and Redemplo approved in China
15/01/2026
Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi’s long-term commitment to China, reinforcing [...]
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
15/01/2026
NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of [...]
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference
15/01/2026
Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presence Next-generation BTK protein degrader APG-3288 receives IND clearance from the U.S. FDA, [...]
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
14/01/2026
-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt maturity PALO ALTO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc [...]
Gradalis’ Vigil® Demonstrates Significant Survival Benefit in cTMB-H / HRP Ovarian Cancer Patients; Phase 2b VITAL Trial Analysis Published in JCO – Precision Oncology
14/01/2026
Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 years (19 months) for placebo (HR=0.23; p=0.008) 7-year OS rate of 45% [...]
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting
14/01/2026
Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder BOSTON and LONDON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals [...]
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
14/01/2026
AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-related peptide (CGRP) antagonist treatment option for both pediatric and adult patients. 1 ,2 [...]
Biomerica Reports Second Quarter Fiscal 2026 Financial Results
14/01/2026
Operating Expenses Decline 4% Year-to-Date Balance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global [...]
New site in Lommel, Belgium: Aqua free successfully completes set-up phase with ISO 9001 certification
14/01/2026
Lommel / Hamburg, 01/15/2026 – Aqua free , a leading provider of innovative drinking-water hygiene solutions, has successfully moved into its new, state-of-the-art facility in Lommel and has now also obtained ISO 9001 [...]
Aviv Clinics Becomes First Undersea & Hyperbaric Medical Society Accredited Center Focused on Treating Emerging Indications in the U.S.
14/01/2026
The accreditation underscores Aviv Clinics’ leadership in clinical excellence, patient safety, and scientific innovation in hyperbaric medicine ORLANDO, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Aviv Clinics , one of the [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Decembre 2025
14/01/2026
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Sanofi: Information concerning the total number of voting rights and shares - December 2025
14/01/2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Ensora Health Becomes New Corporate Partner of ASHA
14/01/2026
Partnership Will Enhance Member SLP Care Through Streamlined Workflow Rockville, MD, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The American Speech-Language-Hearing Association (ASHA) announced today that Ensora Health—the [...]
Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
14/01/2026
First data on blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and intraductal papillary mucinous neoplasms (IPMN) differentiation to be presented in San Diego BERKELEY, Calif. and , Jan [...]
Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation
14/01/2026
Access the segment here SOUTH SAN FRANCISCO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and [...]

Pages